RxDoctor Payments Data

Philip Gauslin

Physician Assistant · Knoxville, TNNPI 1962427732

Payments from drug & device makers

$2,815in general payments, 2019–2025

Across 170 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$560
  • Lilly USA, LLC$484
  • AstraZeneca$363
  • Novartis$254
  • GSK$179
  • Lundbeck LLC$142
  • plus $832 from 18 others

What the payments were for

  • Food & beverage$2,79599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,815 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$109,411
Medicare patients
320
Services billed
4,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$76,887
MounjaroTirzepatide48$56,986
OzempicSemaglutide43$54,402
RexultiBrexpiprazole22$38,858
JardianceEmpagliflozin18$29,800
MyrbetriqMirabegron36$20,463
Varenicline Tartrate11$1,903
Rosuvastatin Calcium187$1,467
Novolog FlexpenInsulin Aspart13$1,435
PaxlovidNirmatrelvir/Ritonavir12$1,429
Testosterone19$1,416
Trazodone Hcl57$1,335
Levothyroxine Sodium131$1,271
Ezetimibe52$1,212
Albuterol Sulfate HfaAlbuterol Sulfate33$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$85$78,316101 claims
Lilly USA, LLCMounjaro$484$56,98648 claims
Novo NordiskOzempic$560$54,40243 claims
Otsuka America Pharmaceutical, Inc.Rexulti$72$38,85822 claims
Boehringer IngelheimJardiance$13$29,80018 claims
Astellas Pharma US IncMyrbetriq$31$20,46336 claims
AbbVieSynthroid$100$79211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →